The Role of Denosumab in the Treatment of Primary Tumors of Bone

J Hand Surg Am. 2023 Sep;48(9):923-930. doi: 10.1016/j.jhsa.2023.02.013. Epub 2023 Apr 7.

Abstract

Many hand surgeons treat benign bone tumors without referral to orthopedic oncologists. However, there have been considerable advances in medical therapy for some of these tumors, with which hand surgeons may not be as familiar. This review focuses on the mechanism and uses of denosumab in the treatment of benign tumors of bone. Although the hand surgeon may not be directly prescribing this therapy, they are often the only physician treating the patient for these conditions. As such, awareness regarding the use of this therapy in reducing pain, decreasing tumor volume, and treatment of potential lung metastases is critical to those taking on these cases without the support of an orthopedic oncologist. This article aims to familiarize hand surgeons with denosumab to help promote knowledge of this therapeutic option and the potential role of this medication in the treatment of primary bone tumors in the hand.

Keywords: RANK; bone tumor; denosumab; giant cell tumor; hand tumor.

Publication types

  • Review

MeSH terms

  • Bone Density Conservation Agents* / therapeutic use
  • Bone Neoplasms* / pathology
  • Bone and Bones
  • Denosumab / therapeutic use
  • Giant Cell Tumor of Bone* / surgery
  • Humans

Substances

  • Denosumab
  • Bone Density Conservation Agents